European Primary Care Cardiovascular Society

Lipids

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

New cholesterol guidelines: aim therapy at patients at highest risk who will benefit most

3' education - Nov. 22, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Lipids and food

10' education - July 11, 2018 - Prof. David Marais - Cape Town, South Africa

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

How do the latest guideline changes affect management of dyslipidaemia in primary care?

10' education - May 26, 2017

What is the evidence base for lipid modification in the guidelines updates?

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 16, 2013 - AHA 2013 - Clyde Yancy

In normal BMI post-menopausal women, trunk fat was associated with higher and leg fat with lower CVD risk

Literature - Sep. 16, 2019 - Chen G-C et al., - Eur Heart J. 2019

Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm
In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach
Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

Global FH registry data reveal that FH patients are insufficiently treated

News - Sep. 9, 2019

ESC 2019 The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

Lifelong modestly lower LDL-c and SBP greatly reduces CV risk

News - Sep. 4, 2019
Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.

ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.

New ESC/EAS dyslipidaemia guidelines: “lower is better” for LDL-c

News - Sep. 4, 2019
The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.

ESC 2019 The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.

In 75-year-olds on statin for primary prevention, stopping therapy was associated with higher CV risk

Literature - Aug. 13, 2019 - Giral P et al.,
Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.

Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

Lowering remnants becomes more important, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Lipid-lowering drug prescription decreases with age but increases with frailty

Literature - June 18, 2019 - Kleipool EEF et al. - Age and Ageing 2019

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

Clinical interest in HDL is historically low, but continued research into HDL yields interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Analysis of 4S data suggest greater benefit of statin therapy in those with inherited high LDL

News - May 29, 2019
An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.